ALSPW Spineway SAS

Acquisition of Spine Innovations a specialist in disc protheses

Acquisition of Spine Innovations a specialist in disc protheses

Press release         Ecully, July 21, 20226 pm

 

Continuation of the targeted external growth strategy

Acquisition of Spine Innovations

Spineway, a specialist in innovative implants for the treatment of severe spine pathologies, announces the acquisition of 100% of the capital of the French company , which specializes in cervical and lumbar disc prostheses.

Spine Innovations, a spin-off from Groupe FH Ortho’s spine activity and majority owned by the investment fund LBO France, has over 25 years of expertise in the field of spine surgery. The company has developed, in collaboration with renowned French surgeons and after more than 10 years of Research & Development, the first viscoelastic lumbar prosthesis called "LP-ESP" which was implanted in 2004 at the Pitié Salpêtrière University Hospital in Paris.

The patented one-piece viscoelastic ESP disc prosthesis (shock absorbing core) allows surgeons to implant a device that mimics the movement and behavior of a natural disc. They are now used in more than 15 countries and Spine Innovations aims to become a major player in the field of disc prostheses worldwide with this innovative technology.

Spine Innovations is based in Lyon and Mulhouse and is supported by a team of 15 people. It markets its products mainly in France, Europe and Australia. For the fiscal year 2020/2021, the company generated sales of €4.2 million, 76% of which were generated internationally. The company is majority owned by the investment fund LBO France, which has been supporting its development since 2020.

Positioned in a segment and territories that are complementary to those of Spineway, Spine Innovations presents numerous synergies to be developed. In line with its growth strategy, this new acquisition will allow Spineway to add a new segment to its product offering, to strengthen its positions in France and internationally and to expand its teams.

Stéphane Le Roux, CEO of Spineway, stated: "I am delighted with this transaction which allows Spineway to accelerate its development and to position itself in a specific segment that we were not addressing, that of disc prosthesis. The integration of Spine Innovations' know-how and teams is perfectly in line with our strategy of targeted external growth and allows us to increase our size and the added value of our offer.

Sandrine Carle, President of Spine Innovations, said: "I am very happy to join the Spineway group. The complementarity of our product lines will facilitate our commercial penetration in France and internationally. The strengthening of our respective teams will also allow us to accelerate our various projects to become a key player in the spine surgery sector."

Arthur Bernardin and Jacques Franchi, Partners of LBO France, declared: "This sale completes our journey in FH Ortho, with the sale in 2020 of the major part of the group to Olympus, and the sale today of the spine entity to Spineway. On each occasion, we have been able to find a quality industrial partner, the one most capable of continuing the development of the business, and we are today very happy to contribute to the emergence of a key French player in the field of spine surgery."

This acquisition was financed entirely in cash and will contribute to the Group's revenues for fiscal year 2022.

With this new external growth operation, Spineway confirms its ambition to become a leading European player in the spine sector.

In this transaction, Spineway was accompanied by HL5 Finance (Inspirit Partners), by Lamy-Lexel Avocats for the legal aspects, by Laurent & Charras for intellectual property and by BBM for auditing. For its part, the LBO France fund was accompanied by Agile Capital Markets and Winston & Strawn for the legal aspects.

Watch the interview with Stéphane Le Roux:

Upcoming: July 25, 2022, Extraordinary General Meeting

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.

Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).

ISIN: FR0011398874 - ALSPW        

Contacts:





SPINEWAY



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060




Eligible PEA / PME





ALSPW Euronext Growth




AELIUM



Finance & Communication



Investor relations



Solène Kennis



 

Attachment



EN
21/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch